Tecentriq 840 mg/14 mL solution for intravenous infusion Images
Generic Name: atezolizumab
This medication has been identified as Tecentriq 840 mg/14 mL solution for intravenous infusion and is used for Hepatocellular Carcinoma, Non Small Cell Lung Cancer, Small Cell Lung Cancer, Alveolar Soft Part Sarcoma, and Melanoma. It belongs to the drug class anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors) and is not a controlled substance.
Images of medication
Tecentriq
- Generic Name
- atezolizumab
- Strength
- 840 mg/14 mL solution for intravenous infusion
- Availability
- Prescription only
- Drug Class
- Anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors)
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Genentech, Inc.
- National Drug Code (NDC)
- 50242-0918
See also:
More about Tecentriq (atezolizumab)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (1)
- Drug images
- Latest FDA alerts (2)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors)
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.